Wikidata

(Q40566975)

English

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

scientific article published on 23 January 2003

In more languages

Statements

title
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
author name string
Jeanette Lundin
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Roland Repp
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Susanne Fredén
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Gunnar Juliusson
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Eija Rosenblad
series ordinal
7
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Geir Tjønnfjord
series ordinal
8
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Tom Wiklund
series ordinal
9
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
Anders Osterborg
series ordinal
10
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
publication date
23 January 2003
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017
page(s)
4267-4272
1 reference
stated in
Europe PubMed Central
PubMed ID
12543862
retrieved
21 September 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q40566975&oldid=2067072635"